CRDL - Cardiol Therapeutics Inc. Stock Price and Quote

CRDL | Cardiol Therapeutics Inc. | [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | Canada

Index	-	P/E	-	EPS (ttm)	-0.46	Insider Own	4.42%	Shs Outstand	64.09M	Perf Week	14.20%
Market Cap	57.89M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	0.00%	Shs Float	61.11M	Perf Month	14.22%
Income	-29.10M	PEG	-	EPS next Q	-0.12	Inst Own	13.99%	Short Float / Ratio	0.24% / 1.44	Perf Quarter	17.20%
Sales	-	P/S	-	EPS this Y	32.40%	Inst Trans	-	Short Interest	0.15M	Perf Half Y	25.99%
Book/sh	0.71	P/B	0.95	EPS next Y	23.50%	ROA	-45.20%	Target Price	-	Perf Year	-40.89%
Cash/sh	0.58	P/C	1.17	EPS next 5Y	-	ROE	-53.00%	52W Range	0.45 - 1.70	Perf YTD	32.14%
Dividend	-	P/FCF	-	EPS past 5Y	-46.60%	ROI	-	52W High	-60.36%	Beta	0.87
Dividend %	-	Quick Ratio	7.30	Sales past 5Y	-	Gross Margin	-	52W Low	49.76%	ATR	0.05
Employees	17	Current Ratio	7.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	58.41	Volatility	8.20% 8.37%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	23.50%	Profit Margin	-	Rel Volume	0.58	Prev Close	0.68
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	103.86K	Price	0.67
Recom	1.50	SMA20	9.25%	SMA50	19.48%	SMA200	-3.86%	Volume	60,580	Change	-0.88%

May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) +8.68%
Mar-29-23 07:27AM	Cardiol Therapeutics Announces Year-End 2022 Update on Operations (Newsfile)
Mar-07-23 07:27AM	Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure (Newsfile)
Jan-17-23 02:59PM	Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis (News Direct)
07:27AM	Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis (Newsfile)
07:27AM	Loading…
Dec-12-22 07:27AM	Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis (Newsfile) +7.30%
Nov-14-22 05:00PM	Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (Newsfile)
Nov-07-22 07:27AM	Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis (Newsfile)
Oct-25-22 06:30AM	Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases (Newsfile) +12.99%
Oct-03-22 07:27AM	Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis (Newsfile)
Sep-28-22 08:20AM	Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America (Newsfile) +11.76%
Sep-27-22 09:05AM	60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago (ACCESSWIRE) -7.27%
Aug-03-22 07:29AM	Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis (Newsfile)
Jul-12-22 06:14AM	Cardiol Therapeutics Inc. (TSE:CRDL): Are Analysts Optimistic? (Simply Wall St.)
Jun-29-22 10:07AM	Cardiol Therapeutics Reports Results of 2022 Annual General Meeting (Newsfile) -8.72%
10:07AM	Loading…
Jun-27-22 10:07AM	Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT (Newsfile) +9.80%
Jun-09-22 04:05PM	Cardiol Therapeutics Announces At-The-Market Equity Offering Program (Newsfile)
May-27-22 01:00PM	Market Movers. Todays Top Stock Picks For New & Trending Opportunities (ACCESSWIRE)
May-24-22 07:00AM	CEO Presenting on the Emerging Growth Conference on May 25 Register Now (GlobeNewswire) -5.70%
May-19-22 07:27AM	Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors (Newsfile) +7.34%
May-17-22 07:27AM	Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis (Newsfile) +12.39%
May-02-22 02:42PM	We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn (Simply Wall St.)
Mar-24-22 07:27AM	Cardiol Therapeutics Announces Year-End 2021 Update on Operations (Newsfile)
Mar-22-22 07:27AM	Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit (Newsfile)
Mar-15-22 07:27AM	Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors (Newsfile) +12.80%
Mar-01-22 07:27AM	Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial (Newsfile)
Feb-02-22 06:30AM	When Will Cardiol Therapeutics Inc. (TSE:CRDL) Turn A Profit? (Simply Wall St.)
Jan-19-22 07:27AM	Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board (Newsfile) -13.42%
Nov-05-21 09:18AM	Cardiol Therapeutics Announces Closing of US$50 Million Public Offering (Newsfile)
Nov-04-21 08:52AM	What You Need To Know About Cardiol Therapeutics Inc.'s (TSE:CRDL) Investor Composition (Simply Wall St.)
08:36AM	Loading…
Nov-03-21 08:36AM	Cardiol Therapeutics Announces Pricing of Public Offering of Units (CNW Group) -25.22%
Nov-02-21 04:04PM	Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units (CNW Group)
Oct-25-21 07:27AM	Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis (Newsfile)
Oct-18-21 07:27AM	Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada (Newsfile) +10.94%
Sep-16-21 07:27AM	Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference (Newsfile) +9.67%
Sep-10-21 04:33PM	Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020 (Newsfile)
Sep-07-21 07:27AM	Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors (Newsfile) +11.26%
Aug-24-21 07:27AM	Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis (Newsfile)
Aug-19-21 06:52AM	When Will Cardiol Therapeutics Inc. (TSE:CRDL) Turn A Profit? (Simply Wall St.)

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience